

DAFTAR PUSTAKA

- Anderson, R.H., 2002. Development and structure of the atrial septum. *Heart* 88: 104–110. doi:10.1136/heart.88.1.104
- Aoki, H., & Horie, M., 2018. Electrical disorders in atrial septal defect: genetics and heritability. *J. Thorac. Dis.* 10: S2848–S2853. doi:10.21037/jtd.2018.02.53
- Ashur, A., Levy, A., Liel-Cohen, N., Sergienko, R., & Kobal, S.L., 2025. Prognostic Value of Pulmonary Hypertension as an Incidental Finding Detected by Echocardiography in Patients Without Known Cardiovascular or Pulmonary Diseases. *JCM* 14: 5044. doi:10.3390/jcm14145044
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, 2002. ATS statement: guidelines for the six-minute walk test. *Am J Respir Crit Care Med* 166: 111–117. doi:10.1164/ajrccm.166.1.at1102
- Bachmann, K.N., Gupta, D.K., Xu, M., Brittain, E., Farber-Eger, E., *et al.*, 2021. Unexpectedly Low Natriuretic Peptide Levels in Patients With Heart Failure. *JACC: Heart Failure* 9: 192–200. doi:10.1016/j.jchf.2020.10.008
- Batton, K.A., Austin, C.O., Bruno, K.A., Burger, C.D., Shapiro, B.P., *et al.*, 2018. Sex differences in pulmonary arterial hypertension: role of infection and autoimmunity in the pathogenesis of disease. *Biol Sex Differ* 9: 15. doi:10.1186/s13293-018-0176-8
- Baumgartner, H., De Backer, J., Babu-Narayan, S.V., Budts, W., Chessa, M., *et al.*, 2021. 2020 ESC Guidelines for the management of adult congenital heart disease. *European Heart Journal* 42: 563–645. doi:10.1093/eurheartj/ehaa554
- Benza, R.L., Gomberg-Maitland, M., Elliott, C.G., Farber, H.W., Foreman, A.J., *et al.*, 2019. Predicting Survival in Patients With Pulmonary Arterial Hypertension. *Chest* 156: 323–337. doi:10.1016/j.chest.2019.02.004
- Benza, R.L., Gomberg-Maitland, M., Miller, D.P., Frost, A., Frantz, R.P., *et al.*, 2012. The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension. *Chest* 141: 354–362. doi:10.1378/chest.11-0676
- Benza, R.L., Kanwar, M.K., Raina, A., Scott, J.V., Zhao, C.L., *et al.*, 2021. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. *Chest* 159: 337–346. doi:10.1016/j.chest.2020.08.2069
- Benza, R.L., Miller, D.P., Gomberg-Maitland, M., Frantz, R.P., Foreman, A.J., *et al.*, 2010a. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). *Circulation* 122: 164–172. doi:10.1161/CIRCULATIONAHA.109.898122
- Benza, R.L., Park, M.H., Keogh, A., & Girgis, R.E., 2007. Management of Pulmonary Arterial Hypertension With a Focus on Combination Therapies. *The Journal of Heart and Lung Transplantation* 26: 437–446. doi:10.1016/j.healun.2007.01.035
- Bouzas, B., & Gatzoulis, M.A., 2005. Pulmonary Arterial Hypertension in Adults With Congenital Heart Disease. *Revista Española de Cardiología (English Edition)* 58: 465–469. doi:10.1016/S1885-5857(06)60723-8
- Celermajer, D.S., 2018. Atrial septal defects: even simple congenital heart diseases can be complicated. *European Heart Journal* 39: 999–1001. doi:10.1093/eurheartj/ehx633
- Chakinala, M.M., Coyne, D.W., Benza, R.L., Frost, A.E., McGoon, M.D., *et al.*, 2018. Impact of declining renal function on outcomes in pulmonary arterial hypertension:

- A REVEAL registry analysis. *The Journal of Heart and Lung Transplantation* 37: 696–705. doi:10.1016/j.healun.2017.10.028
- Craig, R.J., & Selzer, A., 1968. Natural History and Prognosis of Atrial Septal Defect. *Circulation* 37: 805–815. doi:10.1161/01.cir.37.5.805
- Crossman, D.C., 2004. The pathophysiology of myocardial ischaemia. *Heart* 90: 576–580. doi:10.1136/hrt.2003.029017
- D’Alonzo, G.E., Barst, R.J., Ayres, S.M., Bergofsky, E.H., Brundage, B.H., *et al.*, 1991. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry. *Ann Intern Med* 115: 343–349. doi:10.7326/0003-4819-115-5-343
- D’Alto, M., & Mahadevan, V.S., 2012. Pulmonary arterial hypertension associated with congenital heart disease. *Eur Respir Rev* 21: 328–337. doi:10.1183/09059180.00004712
- Damman, K., Navis, G., Smilde, T.D.J., Voors, A.A., Van Der Bij, W., *et al.*, 2007. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. *European J of Heart Fail* 9: 872–878. doi:10.1016/j.ejheart.2007.05.010
- DesJardin, J.T., Kime, N., Kolaitis, N.A., Kronmal, R.A., Lammi, M.R., *et al.*, 2024. Investigating the “sex paradox” in pulmonary arterial hypertension: Results from the Pulmonary Hypertension Association Registry (PHAR). *The Journal of Heart and Lung Transplantation* 43: 901–910. doi:10.1016/j.healun.2024.02.004
- Dewanto, C.V., Hartopo, A.B., & Marsam, R.K., 2023. Penerapan Model Penilaian Risiko Empat Strata pada Pasien Hipertensi Arteri Pulmonal terkait Penyakit Jantung Bawaan Dewasa di Rumah Sakit Umum Pusat Dr. Sardjito. *UGM Repository*.
- Diller, G.-P., & Gatzoulis, M.A., 2007. Pulmonary Vascular Disease in Adults With Congenital Heart Disease. *Circulation* 115: 1039–1050. doi:10.1161/CIRCULATIONAHA.105.592386
- Dinarti, L.K., Anggrahini, D.W., Lilyasari, O., Siswanto, B.B., & Hartopo, A.B., 2021. Pulmonary Arterial Hypertension in Indonesia: Current Status and Local Application of International Guidelines. *Global Heart* 16. doi:10.5334/gh.944
- Dinarti, L.K., Hartopo, A.B., Anggrahini, D.W., Sadewa, A.H., Setianto, B.Y., *et al.*, 2020. Profile of Endothelin-1, Nitric Oxide, and Prostacyclin Levels in Pulmonary Arterial Hypertension Related to Uncorrected Atrial Septal Defect: Results from a Single Center Study in Indonesia. *Cardiol Res Pract* 2020: 7526508. doi:10.1155/2020/7526508
- El-Segaier, M., Pesonen, E., Lukkarinen, S., Peters, K., Ingemansson, J., *et al.*, 2006. Atrial septal defect: a diagnostic approach. *Med Bio Eng Comput* 44: 739–745. doi:10.1007/s11517-006-0094-5
- Engelfriet, P.M., Duffels, M.G.J., Möller, T., Boersma, E., Tijssen, J.G.P., *et al.*, 2007. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease. *Heart* 93: 682–687. doi:10.1136/hrt.2006.098848
- Enright, P.L., & Sherrill, D.L., 1998. Reference equations for the six-minute walk in healthy adults. *Am J Respir Crit Care Med* 158: 1384–1387. doi:10.1164/ajrccm.158.5.9710086
- Farber, H.W., Miller, D.P., McGoon, M.D., Frost, A.E., Benton, W.W., *et al.*, 2015. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. *The Journal of Heart and Lung Transplantation* 34: 362–368. doi:10.1016/j.healun.2014.08.020

- Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., *et al.*, 2016. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Heart J* 37: 67–119. doi:10.1093/eurheartj/ehv317
- Galiè, N., Olschewski, H., Oudiz, R.J., Torres, F., Frost, A., *et al.*, 2008. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2. *Circulation* 117: 3010–3019. doi:10.1161/circulationaha.107.742510
- Golpe, R., Castro-Añón, O., Pérez-de-Llano, L.A., González-Juanatey, C., Muñiz-Fernández, C., *et al.*, 2014. Prognostic significance of six-minute walk test in non-group 1 pulmonary hypertension. *Heart & Lung* 43: 72–76. doi:10.1016/j.hrtlng.2013.08.007
- Grasso, M., Bondavalli, D., Vilardo, V., Cavaliere, C., Gatti, I., *et al.*, 2024. The new 2023 ESC guidelines for the management of cardiomyopathies: a guiding path for cardiologist decisions. *European Heart Journal Supplements* 26: i1–i5. doi:10.1093/eurheartjsupp/suae002
- Habimana, R., Choi, I., Cho, H.J., Kim, D., Lee, K., *et al.*, 2020. Sepsis-induced cardiac dysfunction: a review of pathophysiology. *Acute Crit Care* 35: 57–66. doi:10.4266/acc.2020.00248
- Hanley, J.A., & McNeil, B.J., 1982. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology* 143: 29–36. doi:10.1148/radiology.143.1.7063747
- Heaton, J., Horenstein, M.S., & Kyriakopoulos, C., 2025. Pulmonary Stenosis, in: StatPearls. StatPearls Publishing, Treasure Island (FL).
- Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., *et al.*, 2023. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Respir J* 61: 2200879. doi:10.1183/13993003.00879-2022
- Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., *et al.*, 2022. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Heart Journal* 43: 3618–3731. doi:10.1093/eurheartj/ehac237
- Jarutach, J., Roymanee, S., & Wongwaitawewong, K., 2020. Survival of Patients after Left-to-Right Shunt Repaired of Congenital Heart Defect: A Comparison between Baseline Pulmonary Vascular Resistances. *J Health Sci Med Res.* doi:10.31584/jhsmr.2020755
- Jiang, C., Fang, X., & Fu, W., 2022. The Association of Body Mass Index With Mortality Among Pulmonary Hypertension Patients: A Systematic Review and Meta-Analysis of Cohort Studies. *Front. Public Health* 10: 761904. doi:10.3389/fpubh.2022.761904
- Kaemmerer, H., Gorenflo, M., Huscher, D., Pittrow, D., Apitz, C., *et al.*, 2020. Pulmonary Hypertension in Adults with Congenital Heart Disease: Real-World Data from the International COMPERA-CHD Registry. *JCM* 9: 1456. doi:10.3390/jcm9051456
- Kane, G.C., Maradit-Kremers, H., Slusser, J.P., Scott, C.G., Frantz, R.P., *et al.*, 2011. Integration of Clinical and Hemodynamic Parameters in the Prediction of Long-term Survival in Patients With Pulmonary Arterial Hypertension. *Chest* 139: 1285–1293. doi:10.1378/chest.10-1293

- Karedath, J., Dar, H., Ganipineni, V.D.P., Gorle, S.A., Gaddipati, S., *et al.*, 2023. Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials. *Cureus*. doi:10.7759/cureus.33363
- Keen, J., Prisco, S.Z., & Prins, K.W., 2020. Sex Differences in Right Ventricular Dysfunction: Insights From the Bench to Bedside. *Front Physiol* 11: 623129. doi:10.3389/fphys.2020.623129
- Kheiwa, A., Hari, P., Madabhushi, P., & Varadarajan, P., 2020. Patent foramen ovale and atrial septal defect. *Echocardiography* 37: 2172–2184. doi:10.1111/echo.14646
- Kim, N.H., Fisher, M., Poch, D., Zhao, C., Shah, M., *et al.*, 2020. Long-term outcomes in pulmonary arterial hypertension by functional class: a meta-analysis of randomized controlled trials and observational registries. *Pulm Circ* 10: 2045894020935291. doi:10.1177/2045894020935291
- Kishiki, K., Singh, A., Narang, A., Gomberg-Maitland, M., Goyal, N., *et al.*, 2019. Impact of Severe Pulmonary Arterial Hypertension on the Left Heart and Prognostic Implications. *Journal of the American Society of Echocardiography* 32: 1128–1137. doi:10.1016/j.echo.2019.05.008
- Krisdinarti, L., Hartopo, A.B., Anggrahini, D.W., Sadewa, A.H., Wahab, A.S., *et al.*, 2016. Clinical characteristics of adult uncorrected secundum atrial septal defect: a pilot study. *JMedSci* 48: 89–97. doi:10.19106/JMedSci004802201603
- Kuehne, T., Yilmaz, S., Steendijk, P., Moore, P., Groenink, M., *et al.*, 2004. Magnetic Resonance Imaging Analysis of Right Ventricular Pressure-Volume Loops: In Vivo Validation and Clinical Application in Patients With Pulmonary Hypertension. *Circulation* 110: 2010–2016. doi:10.1161/01.CIR.0000143138.02493.DD
- Lange, S.A., Braun, M.U., Schoen, S.P., & Strasser, R.H., 2013. Latent pulmonary hypertension in atrial septal defect: Dynamic stress echocardiography reveals unapparent pulmonary hypertension and confirms rapid normalisation after ASD closure. *Neth Heart J* 21: 333–343. doi:10.1007/s12471-013-0425-8
- Li, Q., He, Y., Constantine, A., Dimopoulos, K., Zhang, C., *et al.*, 2026. Pulmonary arterial hypertension after congenital heart defect correction: a call for timely diagnosis and careful risk stratification to improve outcomes. *European Heart Journal Open* 6: oiaf172. doi:10.1093/ehjopen/oiaf172
- Li, Q., Yu, H., Xiong, C., Gu, Q., Yu, Z., *et al.*, 2025. Pulmonary arterial compliance as a long-term prognostic indicator in pulmonary arterial hypertension associated with adult congenital heart disease: results from a National multicenter prospective registry. *BMC Cardiovasc Disord* 25: 739. doi:10.1186/s12872-025-05230-5
- Liu, C., Chen, J., Gao, Y., Deng, B., & Liu, K., 2021. Endothelin receptor antagonists for pulmonary arterial hypertension. *Cochrane Database of Systematic Reviews* 2021. doi:10.1002/14651858.CD004434.pub6
- Mandoli, G.E., Landra, F., Chiantini, B., Sciacaluga, C., Pastore, M.C., *et al.*, 2023. Tricuspid Regurgitation Velocity and Mean Pressure Gradient for the Prediction of Pulmonary Hypertension According to the New Hemodynamic Definition. *Diagnostics* 13: 2619. doi:10.3390/diagnostics13162619
- Maron, B.A., Zamanian, R.T., & Waxman, A.B. (Eds.), 2016. *Pulmonary Hypertension: Basic Science to Clinical Medicine*. Springer International Publishing, Cham. doi:10.1007/978-3-319-23594-3
- Martin, S.S., Shapiro, E.P., & Mukherjee, M., 2014. Atrial Septal Defects – Clinical Manifestations, Echo Assessment, and Intervention. *Clin Med Insights Cardiol* 8s1: CMC.S15715. doi:10.4137/CMC.S15715



- Maurer, S.J., Habdank, V., Hörer, J., Ewert, P., & Tutarel, O., 2023. NT-proBNP Is a Predictor of Mortality in Adults with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease. *JCM* 12: 3101. doi:10.3390/jcm12093101
- Maurer, S.J., Stöckemann, K., Pujol, C., Hörer, J., Ewert, P., *et al.*, 2020. Pulmonary Arterial Hypertension Associated with Congenital Heart Disease in Adults over the Age of 40 Years. *JCM* 9: 4071. doi:10.3390/jcm9124071
- McDonagh, T.A., Metra, M., Adamo, M., Gardner, R.S., Baumbach, A., *et al.*, 2021. Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. *European Heart Journal* 42: 4901–4901. doi:10.1093/eurheartj/ehab670
- McGoon, M., Guterman, D., Steen, V., Barst, R., McCrory, D.C., *et al.*, 2004. Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension. *Chest* 126: 14S-34S. doi:10.1378/chest.126.1_suppl.14s
- McLaughlin, V.V., Presberg, K.W., Doyle, R.L., Abman, S.H., McCrory, D.C., *et al.*, 2004. Prognosis of Pulmonary Arterial Hypertension*. *Chest* 126: 78S-92S. doi:10.1378/chest.126.1_suppl.78S
- Menillo, A., Alahmadi, M., & Pearson Shaver, A., 2025. Atrial Septal Defect.
- Mihailovici, A.R., Donoiu, I., Gheonea, D.I., Mirea, O., Târtea, G.C., *et al.*, 2019. NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis - Correlations with Disease Severity. *Med Princ Pract* 28: 432–441. doi:10.1159/000499930
- Miyamoto, S., Nagaya, N., Satoh, T., Kyotani, S., Sakamaki, F., *et al.*, 2000. Clinical Correlates and Prognostic Significance of Six-minute Walk Test in Patients with Primary Pulmonary Hypertension: Comparison with Cardiopulmonary Exercise Testing. *Am J Respir Crit Care Med* 161: 487–492. doi:10.1164/ajrccm.161.2.9906015
- Mocerri, P., Dimopoulos, K., Lioudakis, E., Germanakis, I., Kempny, A., *et al.*, 2012. Echocardiographic Predictors of Outcome in Eisenmenger Syndrome. *Circulation* 126: 1461–1468. doi:10.1161/CIRCULATIONAHA.112.091421
- Monzo, L., Reichenbach, A., Al-Hiti, H., Borlaug, B.A., Havlenova, T., *et al.*, 2021. Acute Unloading Effects of Sildenafil Enhance Right Ventricular–Pulmonary Artery Coupling in Heart Failure. *Journal of Cardiac Failure* 27: 224–232. doi:10.1016/j.cardfail.2020.11.007
- Mozos, I., 2015. Mechanisms Linking Red Blood Cell Disorders and Cardiovascular Diseases. *BioMed Research International* 2015: 1–12. doi:10.1155/2015/682054
- Naeije, R., & Manes, A., 2014. The right ventricle in pulmonary arterial hypertension. *Eur Respir Rev* 23: 476–487. doi:10.1183/09059180.00007414
- Nashat, H., Montanaro, C., Li, W., Kempny, A., Wort, S.J., *et al.*, 2018. Atrial septal defects and pulmonary arterial hypertension. *J. Thorac. Dis.* 10: S2953–S2965. doi:10.21037/jtd.2018.08.92
- Oba, Y., Maduke, T., Fakhouri, E.W., & Goite, Y., 2025. Phosphodiesterase type 5 inhibitor plus endothelin receptor antagonist compared to either alone for group 1 pulmonary arterial hypertension. *Cochrane Database of Systematic Reviews* 2025. doi:10.1002/14651858.CD015824.pub2
- Osuna, P.M., Udovicic, M., & Sharma, M.D., 2017. Hypothyroidism and the Heart. *Methodist DeBakey Cardiovascular Journal* 13: 60. doi:10.14797/mdcj-13-2-60
- Padervinskienė, L., Krivickienė, A., Hoppenot, D., Miliuskas, S., Basevičius, A., *et al.*, 2019. Prognostic Value of Left Ventricular Function and Mechanics in Pulmonary

- Hypertension: A Pilot Cardiovascular Magnetic Resonance Feature Tracking Study. *Medicina* 55: 73. doi:10.3390/medicina55030073
- PAH Initiative, 2024. Optimizing PAH Outcome - A Patient Monitoring Guide.
- Palacios-Moguel, P., Cueto-Robledo, G., González-Pacheco, H., Ortega-Hernández, J., Torres-Rojas, M.B., *et al.*, 2025. The role of the TAPSE/sPAP ratio as a predictor of mortality in Pulmonary Arterial Hypertension: Its value for patient risk stratification. *JHLT Open* 7: 100168. doi:10.1016/j.jhlto.2024.100168
- Patsiou, V., Arvanitaki, A., Farmakis, I.T., Anthi, A., Demerouti, E., *et al.*, 2025. Survival prospects of pulmonary arterial hypertension associated with congenital heart disease: Insights from the HOPE registry. *International Journal of Cardiology* 421: 132894. doi:10.1016/j.ijcard.2024.132894
- Pestelli, G., Fiorencis, A., Trevisan, F., Luisi, G.A., Smarrazzo, V., *et al.*, 2021. New measures of right ventricle-pulmonary artery coupling in heart failure: An all-cause mortality echocardiographic study. *International Journal of Cardiology* 329: 234–241. doi:10.1016/j.ijcard.2020.12.057
- Pisetsky, D.S., 2023. Pathogenesis of autoimmune disease. *Nat Rev Nephrol* 19: 509–524. doi:10.1038/s41581-023-00720-1
- Plácido, R., & Martins, S., 2015. Predictors of Functional Capacity in Patients with Pulmonary Hypertension. *J Pulm Respir Med* 05. doi:10.4172/2161-105X.1000290
- Rådegran, G., Kjellström, B., Ekmehag, B., Larsen, F., Rundqvist, B., *et al.*, 2016. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014. *Scandinavian Cardiovascular Journal* 50: 243–250. doi:10.1080/14017431.2016.1185532
- Rafikova, O., Rafikov, R., Meadows, M.L., Kangath, A., Jonigk, D., *et al.*, 2015. The Sexual Dimorphism Associated with Pulmonary Hypertension Corresponds to a Fibrotic Phenotype. *Pulm. circ.* 5: 184–197. doi:10.1086/679724
- Roch, A., 2007. What does high NT-proBNP mean in septic shock patients? A part of the puzzle. *Crit Care* 11: 122. doi:10.1186/cc5728
- Rochmat, M.B., Setianto, B.Y., Anggrahini, D.W., Dinarti, L.K., & Hartopo, A.B., 2025. Systolic Blood Pressure, Cardiac Index and Eisenmenger Syndrome are Predictors of Mortality in Pulmonary Arterial Hypertension-associated with Congenital Heart Disease: An Analysis from the COHARD-PH registry. *ijc* 45. doi:10.30701/ijc.1623
- Rodrigues, S. de O., Cunha, C.M.C. da, Soares, G.M.V., Silva, P.L., Silva, A.R., *et al.*, 2021. Mechanisms, Pathophysiology and Currently Proposed Treatments of Chronic Obstructive Pulmonary Disease. *Pharmaceuticals (Basel)* 14: 979. doi:10.3390/ph14100979
- Rodriguez-Arias, J.J., & García-Álvarez, A., 2021. Sex Differences in Pulmonary Hypertension. *Front. Aging* 2: 727558. doi:10.3389/fragi.2021.727558
- Rubáčková Popelová, J., Tomková, M., Tomek, J., & Živná, R., 2022. Long-Term Survival of Adult Patients With Atrial Septal Defect With Regards to Defect Closure and Pulmonary Hypertension. *Front Cardiovasc Med* 9: 867012. doi:10.3389/fcvm.2022.867012
- Sahay, S., Bhatt, J., Beshay, S., Guha, A., Nguyen, D.T., *et al.*, 2022. E-REVEAL Lite 2.0 scoring for early prediction of disease progression in pulmonary arterial hypertension. *Pulm. circ.* 12: e12026. doi:10.1002/pul2.12026
- Sahay, S., Villasmil Hernandez, N., Wang, F., Wooten, M., Nguyen, D.T., *et al.*, 2024. Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension. *CHEST* 166: 373–387. doi:10.1016/j.chest.2024.02.052



- Schuuring, M.J., Van Riel, A.C.M.J., Vis, J.C., Duffels, M.G., Van Dijk, A.P.J., *et al.*, 2015. New predictors of mortality in adults with congenital heart disease and pulmonary hypertension: Midterm outcome of a prospective study. *International Journal of Cardiology* 181: 270–276. doi:10.1016/j.ijcard.2014.11.222
- Shah, S.J., Thenappan, T., Rich, S., Tian, L., Archer, S.L., *et al.*, 2008. Association of Serum Creatinine With Abnormal Hemodynamics and Mortality in Pulmonary Arterial Hypertension. *Circulation* 117: 2475–2483. doi:10.1161/CIRCULATIONAHA.107.719500
- Silvestry, F.E., Cohen, M.S., Armsby, L.B., Burkule, N.J., Fleishman, C.E., *et al.*, 2015. Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions. *Journal of the American Society of Echocardiography* 28: 910–958. doi:10.1016/j.echo.2015.05.015
- Souza, R., Channick, R.N., Delcroix, M., Galiè, N., Ghofrani, H.-A., *et al.*, 2018. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. *PLoS One* 13: e0193226. doi:10.1371/journal.pone.0193226
- Tabucanon, T., & Tang, W.H.W., 2020. Right Heart Failure and Cardiorenal Syndrome. *Cardiology Clinics* 38: 185–202. doi:10.1016/j.ccl.2020.01.004
- Tagore, R., Ling, L.H., Yang, H., Daw, H.-Y., Chan, Y.-H., *et al.*, 2008. Natriuretic peptides in chronic kidney disease. *Clin J Am Soc Nephrol* 3: 1644–1651. doi:10.2215/CJN.00850208
- Tello, K., Dalmer, A., Axmann, J., Vanderpool, R., Ghofrani, H.A., *et al.*, 2019a. Reserve of Right Ventricular-Arterial Coupling in the Setting of Chronic Overload. *Circ: Heart Failure* 12. doi:10.1161/circheartfailure.118.005512
- Tello, K., Wan, J., Dalmer, A., Vanderpool, R., Ghofrani, H.A., *et al.*, 2019b. Validation of the Tricuspid Annular Plane Systolic Excursion/Systolic Pulmonary Artery Pressure Ratio for the Assessment of Right Ventricular-Arterial Coupling in Severe Pulmonary Hypertension. *Circ: Cardiovascular Imaging* 12: e009047. doi:10.1161/CIRCIMAGING.119.009047
- Thenappan, T., Ormiston, M.L., Ryan, J.J., & Archer, S.L., 2018. Pulmonary arterial hypertension: pathogenesis and clinical management. *BMJ* j5492. doi:10.1136/bmj.j5492
- Todaro, M.C., Caretj, S., Zito, C., Trifirò, M.P., Consolo, G., *et al.*, 2020. Echocardiographic evaluation of right ventricular-arterial coupling in pulmonary hypertension. *Am J Cardiovasc Dis* 10: 272–283.
- Topyła-Putowska, W., Tomaszewski, M., Wojtkowska, A., Styczeń, A., & Wysokiński, A., 2023. Tricuspid Regurgitation Velocity/Tricuspid Annular Plane Systolic Excursion (TRV/TAPSE) Ratio as a Novel Indicator of Disease Severity and Prognosis in Patients with Precapillary Pulmonary Hypertension. *Diseases* 11: 117. doi:10.3390/diseases11030117
- Torres, A.J., 2018. Hemodynamic assessment of atrial septal defects. *J. Thorac. Dis.* 10: S2882–S2889. doi:10.21037/jtd.2018.02.17
- Van Der Linde, D., Konings, E.E.M., Slager, M.A., Witsenburg, M., Helbing, W.A., *et al.*, 2011. Birth Prevalence of Congenital Heart Disease Worldwide. *Journal of the American College of Cardiology* 58: 2241–2247. doi:10.1016/j.jacc.2011.08.025
- Vanderpool, R.R., Pinsky, M.R., Naeije, R., Deible, C., Kosaraju, V., *et al.*, 2015. RV-pulmonary arterial coupling predicts outcome in patients referred for pulmonary hypertension. *Heart* 101: 37–43. doi:10.1136/heartjnl-2014-306142

- Vicenzi, M., Caravita, S., Rota, I., Casella, R., Deboeck, G., *et al.*, 2022. The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension. *PLoS ONE* 17: e0265059. doi:10.1371/journal.pone.0265059
- Vijarnsorn, C., Durongpisitkul, K., Chungsomprasong, P., Bositthipichet, D., Ketsara, S., *et al.*, 2018. Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts. *PLoS ONE* 13: e0195092. doi:10.1371/journal.pone.0195092
- Vijayalakshmi, I.B., Rao, P.S., & Chugh, R., 2013. A comprehensive approach to congenital heart diseases, 1st ed. ed. Jaypee Brothers Medical Publishers (P) LTD, New Delhi.
- Vraka, A., Diamanti, E., Kularatne, M., Yerly, P., Lador, F., *et al.*, 2023. Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives. *J Clin Med* 12: 4349. doi:10.3390/jcm12134349
- Vrints, C., Andreotti, F., Koskinas, K.C., Rossello, X., Adamo, M., *et al.*, 2024. 2024 ESC Guidelines for the management of chronic coronary syndromes. *European Heart Journal* 45: 3415–3537. doi:10.1093/eurheartj/ehae177
- Welsh, P., Campbell, R.T., Mooney, L., Kimenai, D.M., Hayward, C., *et al.*, 2022. Reference Ranges for NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) and Risk Factors for Higher NT-proBNP Concentrations in a Large General Population Cohort. *Circ: Heart Failure* 15. doi:10.1161/CIRCHEARTFAILURE.121.009427
- Wijeratne, D.T., Lajkosz, K., Brogly, S.B., Lougheed, M.D., Jiang, L., *et al.*, 2018. Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada. *Circ: Cardiovascular Quality and Outcomes* 11. doi:10.1161/circoutcomes.117.003973
- Willis, M.S., Lee, E.S., & Grenache, D.G., 2005. Effect of anemia on plasma concentrations of NT-proBNP. *Clinica Chimica Acta* 358: 175–181. doi:10.1016/j.cccn.2005.03.009
- Yang, Y., Chen, H., Dong, Q., Liao, K., & Huang, W., 2023. Severity of functional tricuspid regurgitation is associated with mortality in patients with pulmonary hypertension in long-term follow-up. *Pulm. circ.* 13: e12222. doi:10.1002/pul2.12222
- Yogeswaran, A., Annis, J.S., Funderich, M., Wilhelm, J., Kiely, D.G., *et al.*, 2026. Male survival disadvantage in pulmonary hypertension: independent of aetiology, age, disease severity, comorbidities and treatment. *eBioMedicine* 123: 106063. doi:10.1016/j.ebiom.2025.106063
- Yolanda, D.A., Dinarti, L.K., & Gharini, P.P.R., 2023. Penilaian Right Ventricle Pulmonary Artery Coupling Sebagai Faktor Prediksi Kematian Pada Pasien Defek Septum Atrium yang Belum Dikoreksi dengan Hipertensi Pulmonal. *Repository Universitas Gadjah Mada*.
- Zhang, H., Li, X., Zhang, N., & Tian, L., 2023. Effect of thyroid dysfunction on N-terminal pro-B-type natriuretic peptide levels: A systematic review and meta-analysis. *Front Endocrinol (Lausanne)* 14: 1083171. doi:10.3389/fendo.2023.1083171
- Zuk, M., Migdal, A., Jagiellowicz-Kowalska, D., Mazurkiewicz, K., Sadel-Wieczorek, A., *et al.*, 2017. Six-Minute Walk Test in Evaluation of Children with Pulmonary Arterial Hypertension. *Pediatr Cardiol* 38: 754–761. doi:10.1007/s00246-017-1575-z